discussed the evolving treatment landscape of amyloidosis. Read these and more top stories in cardiology below: High prevalence of atherosclerosis detected in patients entering lung cancer therapy ...

The experimental group had significantly higher levels of white blood cells, neutrophils, C-reactive protein (CRP), serum amyloid A (SAA), neutrophil-to-lymphocyte ratio (NLR), and C-reactive protein ...

Two years later, his failing heart was worsening. Fluid was building up in his body. "I was sleeping all the time," he said. ...

AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that support a wide moat. The strong replenishment of new drugs sets ...

Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) had its price objective dropped by equities researchers at Truist ...

lung cancer or even multiple myeloma, which is five to ten times more common than amyloidosis," Hagen told WBBM. Thanks to Loyola and a rigorous treatment plan, Nyhoff achieved remission.

Orbis Medicines, a leader in oral macrocycle drug discovery, today announces the appointment of Mikael Dolsten, M.D., Ph.D., former Chief Scientific O ...

Y Intercept Hong Kong Ltd acquired a new stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) in the ...

Lantheus Holdings, Inc.'s stock soars 55%, fueled by Pylarify and strategic acquisitions in Alzheimer's and oncology. Click ...

Clare Bryant, Professor of Innate Immunity, is a molecular detective. She looks at how bodies defend themselves and tries to ...